Till Milde
- Genetics top 1%
- Glioma Diagnosis and Treatment 37
- Oncology top 2%
- Molecular Biology top 2%
- Histone Deacetylase Inhibitors Research 21
- Protein Degradation and Inhibitors 17
- Chromatin Remodeling and Cancer 8
- Epigenetics and DNA Methylation 5
- Ubiquitin and proteasome pathways 4
- Cancer Research top 5%
- Neurology top 2%
- Neuroblastoma Research and Treatments 19
-
- Ocular Oncology and Treatments 4
- Co-authors
- Olaf WittIna OehmeHedwig E. DeubzerStefan M. PfisterMarco LodriniShahin RafiiNicholas W. GaleDavid M. Valenzuela
- Cited by
- GeneticsOncologyMolecular Biology
- Journals
- Neuro-Oncology (11 papers)Journal of Neuro-Oncology (6 papers)Journal of Clinical Investigation (4 papers)
- Partner nations
- GermanyUnited StatesUnited Kingdom
In The Last Decade
Till Milde
66 papers receiving 3.8k citations
Hit Papers
Peers
Comparison fields: 5 of 114
- Genetics 712
- Oncology 1.3k
- Molecular Biology 2.5k
- Cancer Research 544
- Neurology 504
Countries citing papers authored by Till Milde
This map shows the geographic impact of Till Milde's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Till Milde with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Till Milde more than expected).
Fields of papers citing papers by Till Milde
This network shows the impact of papers produced by Till Milde. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Till Milde. The network helps show where Till Milde may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Till Milde, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 0 | |
| 2 | 2025 | 1 | |
| 3 | 2024 | 0 | |
| 4 | 2024 | 1 | |
| 5 | 2024 | 0 | |
| 6 | 2023 | 3 | |
| 7 | 2023 | 3 | |
| 8 | 2023 | 2 | |
| 9 | 2023 | 1 | |
| 10 | 2022 | 7 | |
| 11 | 2021 | 9 | |
| 12 | 2021 | 63 | |
| 13 | 2017 | 18 | |
| 14 | 2017 | 31 | |
| 15 | 2013 | 24 | |
| 16 | 2010 | 158 | |
| 17 | 2009 | 53 | |
| 18 | HDAC family: What are the cancer relevant targets?breakdown → | 2008 | 871 |
| 19 | 2006 | 80 | |
| 20 | 2005 | 3 |
About Till Milde
Till Milde is a scholar working on Genetics, Neurology, Molecular Biology, Oncology and Hematology, having authored 74 papers that have together received 3.9k indexed citations. Recurring topics across this work include Glioma Diagnosis and Treatment (37 papers), Histone Deacetylase Inhibitors Research (21 papers), Neuroblastoma Research and Treatments (19 papers), Protein Degradation and Inhibitors (17 papers), Chromatin Remodeling and Cancer (8 papers), Epigenetics and DNA Methylation (5 papers), Ubiquitin and proteasome pathways (4 papers) and Ocular Oncology and Treatments (4 papers). The work is most often cited by research in Genetics (712 citations), Oncology (1.3k citations), Molecular Biology (2.5k citations), Cancer Research (544 citations) and Neurology (504 citations). Till Milde has collaborated with scholars based in Germany, United States and United Kingdom. Frequent co-authors include Olaf Witt, Ina Oehme, Hedwig E. Deubzer, Stefan M. Pfister, Marco Lodrini, Shahin Rafii, Nicholas W. Gale, David M. Valenzuela, George D. Yancopoulos and Andrey Korshunov. Their work appears in journals such as Neuro-Oncology, Journal of Neuro-Oncology, Journal of Clinical Investigation, Cancers and Brain Pathology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.